American Journal of Clinical Dermatology

, Volume 1, Issue 1, pp 19–26 | Cite as


Treatment, Quality of Life, and Economic Issues
  • Boni E. Elewski
Review Article


Onychomycosis is a public health concern because of its high worldwide incidence and prevalence, and its potential for spread of fungal elements to others, as well as complications such as cellulitis, bacterial infection, pain, and extensive dermatophytic infections. The incidence of onychomycosis has been increasing, particularly in individuals over 60 years of age, patients with HIV infection, and patients with diabetes mellitus. Onychomycosis may impact upon physical, functional, psychosocial, and emotional aspects of life. Difficulty walking, wearing shoes, and embarrassment are common complaints. Quantification of such quality-of-life changes are significant to clinical practice in that many factors can affect overall patient health. In light of the potential clinical implications on physical and mental health, onychomycosis should be considered a medical condition that deserves rigorous clinical management.

Onychomycosis can be treated effectively and with comparative safety with the new generation of oral antifungal agents (itraconazole, fluconazole and terbinafine). Significantly improved pharmacokinetic and pharmacodynamic profiles permit markedly reduced duration of administration, individual drug exposure, and ultimately enhanced patient compliance and satisfaction with therapy. In addition, a number of pharmacoeconomic studies have documented the cost effectiveness of these newer agents compared with both traditional pharmacologic treatment and topical therapies. The currency figures quoted are 1997 values. With regard to continuous oral antifungal regimens, terbinafine therapy has been found to be most cost effective in the treatment of toenail onychomycosis, with a drug acquisition cost of $US522.50. However, improved safety, tolerability, efficacy and cost effectiveness have been documented with itraconazole intermittent, pulse regimens. With itraconazole pulse therapy, the drug acquisition cost decreases to $US488.90. Additionally, the total cost of medical management is less for itraconazole therapy compared with that of terbinafine ($US261.00 vs $US306.00). Because sensitivity analyses for itraconazole and terbinafine have been found to be somewhat comparable in terms of mycological cure, clinical response, and relapse rates, other variables such as safety and efficacy profiles, and patient attitudes and expectations toward therapy need to be considered when formulating an onychomycosis pharmacologic treatment plan. The drug aquisition cost of fluconazole given as a 300mg dose once weekly for 6 months is $US562.76 and given as a 150mg dose once weekly (for 6 months) $US281.38.


Fluconazole Itraconazole Terbinafine Griseofulvin Tinea Capitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Zaias N. Onychomycosis. Arch Dermatol 1972; 105: 263–274PubMedCrossRefGoogle Scholar
  2. 2.
    Kemna M.E., Elewski B.E. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996 Oct; 35 (4): 539–542PubMedCrossRefGoogle Scholar
  3. 3.
    De Donker P.R.G., Scher R.K., Baran R.L., et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997 Feb; 36 (2): 173–177CrossRefGoogle Scholar
  4. 4.
    Kam K.M., Au W.F., Wong P.Y., et al. Onychomycosis in Hong Kong. Int J Dermatol 1997 Oct; 36 (10): 757–761PubMedCrossRefGoogle Scholar
  5. 5.
    Mercantini R., Marsella R., Moretto D. Onychomycosis in Rome, Italy. Mycopathologia 1996; 136 (1): 25–32PubMedCrossRefGoogle Scholar
  6. 6.
    Ginter G., Rieger E., Heigl K., et al. Increasing frequency of onychomycosis — is there a change in the spectrum of infectious agents? Mycoses 1996; 39 Suppl. 1: 118–122PubMedCrossRefGoogle Scholar
  7. 7.
    Velez A., Linares M.J., Fenandez-Roldan J.C., et al. Study of onychomycosis in Cordoba, Spain: prevailing fungi and pattern of infection. Mycopathologia 1997; 137 (1): 1–8PubMedCrossRefGoogle Scholar
  8. 8.
    Summerbell R.C. Epidemiology and ecology of onychomycosis. Dermatology 1997; 194 Suppl. 1: 32–36PubMedCrossRefGoogle Scholar
  9. 9.
    Ellis D.H., Marley J.E., Watson A.B., et al. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatol 1997; 194 Suppl. 1: 40–42CrossRefGoogle Scholar
  10. 10.
    Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994 Sep; 31 (3): S21–S25PubMedCrossRefGoogle Scholar
  11. 11.
    Scher R.K. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 Suppl. 43: 15PubMedCrossRefGoogle Scholar
  12. 12.
    Gupta A.K., Jain H.C., Lynde C.W., et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists∝ offices in Ontario, Canada — a multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783–787PubMedCrossRefGoogle Scholar
  13. 13.
    Roberts D.T. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992 Feb; 126 Suppl. 39: 23–27PubMedCrossRefGoogle Scholar
  14. 14.
    Elewski B.E., Charif M.A. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997 Sep; 133 (9): 1172–1173PubMedCrossRefGoogle Scholar
  15. 15.
    Heikkila H., Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol1995 Nov; 133 (5): 699–703CrossRefGoogle Scholar
  16. 16.
    Gupta A.K., Sibbald R.G., Lynde C.W., et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997 Mar; 36 (3): 395–402PubMedCrossRefGoogle Scholar
  17. 17.
    Zienicke H.C., Korting H.C., Likacs A., et al. Dermatophytosis in children and adolescents: epidemiological, clinical, and microbiological aspects changing with age. J Dermatol 1991 Aug; 18 (8): 438–446PubMedGoogle Scholar
  18. 18.
    Philpot C.M., Shuttleworth D. Dermatophyte onychomycosis in children. Clin Exp Dermatol 1989 May; 14 (3): 203–25PubMedCrossRefGoogle Scholar
  19. 19.
    Scher R.K. Onychomycosis: a significant medical disorder. J Am Acad Dermatol1996 Sep; 35 (3): S2–S5CrossRefGoogle Scholar
  20. 20.
    Odom R.B. Common superficial fungal infections in immunosuppressed patients.J Am Acad Dermatol 1994 Sep; 31 (3): S56–S59PubMedCrossRefGoogle Scholar
  21. 21.
    Levy L.A. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997 Dec; 87 (12): 546–550PubMedGoogle Scholar
  22. 22.
    Gregory N.Special patient populations: onychomycosis in the HIV-positive patient.J Am Acad Dermatol 1996 Sep; 35 (3): S13–S16PubMedCrossRefGoogle Scholar
  23. 23.
    Gupta A.K., Lynde C.W., Jain H.C., et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997 May; 136 (5): 786–789PubMedCrossRefGoogle Scholar
  24. 24.
    Gupta A.K., Konnikov N., MacDonald P., et al. Prevalence of onychomycosis in diabetics: a North American survey. Poster presented at the Fifth International Summit on Cutaneous Antifungal Therapy; 1998 Jun 15-17; SingaporeGoogle Scholar
  25. 25.
    US Department of Health and Human Services, Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA; 1997Google Scholar
  26. 26.
    US Department of Health and Human Services, Centers for Disease Control and Prevention. Diabetes. A Serious Public Health Problem. At-A-Glance. US Departmentof Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA; 1998Google Scholar
  27. 27.
    Drake L.A. Impact of onychomycosis on quality of life. J Am Podiatr Med Assoc1997 Nov; 87 (11): 507–511Google Scholar
  28. 28.
    Shuster S., Fisher G.H., Harris E., et al. The effect of skin disease on self image. Br J Dermatol 1978 July; 99 Suppl. 16: 18–19PubMedCrossRefGoogle Scholar
  29. 29.
    Wessely S.C., Lewis G.H. The classification of psychiatric morbidity in attenders at a dermatology clinic. Br J Psychiatry 1989; 155: 686–691PubMedGoogle Scholar
  30. 30.
    Lubeck D.P. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 1998 May; 38 (5): S64–S68PubMedCrossRefGoogle Scholar
  31. 31.
    Lubeck D.P., McNulty P.P., Fifer S.K., et al. Quality of life of persons with onychomycosis. Qual Life Res 1993; 2: 341–348PubMedCrossRefGoogle Scholar
  32. 32.
    Schein J.R., Gause D., Stier D.M., et al. Onychomycosis. Baseline results of an observational study. J Am Podiatr Med Assoc 1997 Nov; 87 (11): 512–519PubMedGoogle Scholar
  33. 33.
    Elewski B.E. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36: 754–756PubMedCrossRefGoogle Scholar
  34. 34.
    Goldsmith H. Practice management and managed-care issues in onychomycosis. J Am Podiatr Assoc 1997; 87 (11): 532–539Google Scholar
  35. 35.
    Whittam L.R., Hay R.J. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87–89PubMedCrossRefGoogle Scholar
  36. 36.
    Drake L.A., Scher R.K., Smith E.B., et al. Effect of onychomycosis on quality of life.J Am Acad Dermatol 1998; 38 (5): 702–704PubMedCrossRefGoogle Scholar
  37. 37.
    Data on file, Grifulvin V® (griseofulvin), Ortho Dermatologics, Skillman, NJGoogle Scholar
  38. 38.
    Data on file, Nizoral® (ketoconazole), Janssen Pharmaceutica, Titusville, NJGoogle Scholar
  39. 39.
    Del Rosso J.C., Gupta A.K. Oral antifungal agents: recognition and management of adverse reactions. Today’s Therapeutic Trends 1997; 15 (2): 75–84Google Scholar
  40. 40.
    Del Rosso J.C. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 1997; 97 (6): 339–346PubMedGoogle Scholar
  41. 41.
    Data on file, Diflucan® (fluconazole), Pfizer, Inc, New York, NYGoogle Scholar
  42. 42.
    Data on file, Sporanox® (itraconazole), Janssen Pharmaceutica, Titusville, NJGoogle Scholar
  43. 43.
    Data on file, Lamisil® (terbinafine hydrochloride), Novartis Pharmaceuticals Corporation, East Hanover, NJGoogle Scholar
  44. 44.
    Del Rosso J.C., Gupta A.K. The spectrum of utility of oral antifungal agents: from the petri dish to the patient. Today’s Therapeutic Trends 1997; 15 (3): 179–189Google Scholar
  45. 45.
    Heykants J., Van Peer A, Van de Velde V., et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 Suppl. 1: 67–87PubMedGoogle Scholar
  46. 46.
    Matthieu L., De Donker P., Cauwenbergh G., et al. Itraconazole penetrates the nail via the nail matrix and the nail bed — an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374–376PubMedCrossRefGoogle Scholar
  47. 47.
    De Donker P., Gupta A.K., Marynissen G., et al. Itraconazole pulse therapy for onychomycosisand dermatomycoses: an overview. J Am Acad Dermatol 1997; 37 (6): 969–974CrossRefGoogle Scholar
  48. 48.
    De Donker P, Gupta AK, Del Rosso JC, et al. Update on the safety of itraconazole pulse therapy in onychomycosis. Poster presentation at the American Academy of Dermatology Academy’ 98, Chicago, ILGoogle Scholar
  49. 49.
    National Institute on Aging. Progress Report on Alzheimers Disease 1997. Bethesda, MD: National Institute on Aging; 1997Google Scholar
  50. 50.
    Rosenbach ML, Schneider JE. The burden of onychomycosis in the Medicare population. Health Economic Research Inc., Sandoz Pharmaceuticals Corporation. On file.Google Scholar
  51. 51.
    American Podiatric Medical Association. 1997 Diabetes Survey. Statistical results.J Am Podiatr Assoc 1997; 87 (12): 575–583Google Scholar
  52. 52.
    US Department of Health and Human Services, Food and Drug Administration. Dermatological Drugs Advisory Committee Meeting #40 [transcript]. Center for Drug Evaluation and Research. 1994 Sep 23, Rockville, MDGoogle Scholar
  53. 53.
    Sinclair R. What is the cost of onychomycosis? Australas J Dermatol 1998; 39 (2): 131–132PubMedGoogle Scholar
  54. 54.
    Einarson T.R., Arikian S.R., Shear N.H. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 Suppl. 43: 32–34PubMedCrossRefGoogle Scholar
  55. 55.
    Marchetti A., Tak Piech C., McGhan W.F., et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18 (4): 757–777PubMedCrossRefGoogle Scholar
  56. 56.
    Gupta A.K. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmacoeconomics1998 Feb; 13 (2): 243–256CrossRefGoogle Scholar
  57. 57.
    Van Doorslaer E.K.A., Tormans G., Gupta A.K., et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology1996;193: 239–244CrossRefGoogle Scholar
  58. 58.
    Bootman J.L. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials. J Am Acad Dermatol 1998 May; 38 (5): S69–S72PubMedCrossRefGoogle Scholar
  59. 59.
    Gupta A.K. De Donker P., Scher R.K., et al. Itraconazole for the treatment of onychomycosis.Int J Dermatol 1998; 37: 303–308PubMedCrossRefGoogle Scholar
  60. 60.
    Abdel-Rahman S.M., Marcucci K., Boge T., et al. Inhibition of cytochrome P4502D6 (CYP2D6) by terbinafine (Ter) in vitro. Clin Pharmacol Ther 1998; 65 (2): 135Google Scholar
  61. 61.
    Abdel-Rahman S.M., Gotschall R.R., Kauffman R.E., et al. Inhibition of cytochrome P4502D6 (CYP2D6) by terbinafine (Ter) in vivo. Clin Pharmacol Ther 1998; 65 (2): 135Google Scholar
  62. 62.
    Gupta A.K., Lynde C.W., Lauzon G.J., et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol1998; 138 (3): 529–532CrossRefGoogle Scholar
  63. 63.
    Gupta A.K. Terbinafine: an update. J Am Acad Dermatol 1997; 37 (6): 979–988PubMedCrossRefGoogle Scholar
  64. 64.
    Gupta A.K., Sibbald R.G., Knowles S.R. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997; 36 (5): 858–862PubMedCrossRefGoogle Scholar
  65. 65.
    Kempinaire A., De Raeve L., Merckx M. Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result. J Am Acad Dermatol 1997; 37 (4):653–655PubMedCrossRefGoogle Scholar
  66. 66.
    Carstens J., Wendelboe P., Søgaard H., et al. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol (Stockh) 1994 Sep; 74 (5): 391–392Google Scholar
  67. 67.
    Gupta A.K., Gonder J.R., Shear N.H., et al. The development of green vision in association with terbinafine therapy. Arch Dermatol 1996; 132: 845–846PubMedCrossRefGoogle Scholar
  68. 68.
    Beutler M., Hartmann K., Kuhn M., et al. Taste disorders and terbinafine. BMJ 1993; 307: 26PubMedCrossRefGoogle Scholar
  69. 69.
    Back D. Loss of taste and terbinafine. Lancet 1992; 340: 252PubMedCrossRefGoogle Scholar
  70. 70.
    Juhlin L. Loss of taste and terbinafine. Lancet 1992; 339: 1483PubMedCrossRefGoogle Scholar
  71. 71.
    Agarwal K., Manas D., Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med 1999; 340 (16): 1292–1293PubMedCrossRefGoogle Scholar
  72. 72.
    Nolting S.K., Sanchez Carazo J., De Boulle K. et al. Oral treatment schedules for onychomycosis: a study of patient preference. Int J Dermatol 1998; 37: 454–456PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of Alabama at Birmingham, The Eye Foundation Building Suite 414BirmingUSA

Personalised recommendations